ATE282428T1 - Pharmazeutische dosierungsform von amorphem nilfenavir mesylat - Google Patents

Pharmazeutische dosierungsform von amorphem nilfenavir mesylat

Info

Publication number
ATE282428T1
ATE282428T1 AT02748680T AT02748680T ATE282428T1 AT E282428 T1 ATE282428 T1 AT E282428T1 AT 02748680 T AT02748680 T AT 02748680T AT 02748680 T AT02748680 T AT 02748680T AT E282428 T1 ATE282428 T1 AT E282428T1
Authority
AT
Austria
Prior art keywords
nilfenavir
amorphic
mesylate
dosage form
pharmaceutical dosage
Prior art date
Application number
AT02748680T
Other languages
English (en)
Inventor
Martin Howard Infeld
Wantanee Phuapradit
Navnit Hargovindas Shah
Lin Zhang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE282428T1 publication Critical patent/ATE282428T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT02748680T 2001-05-03 2002-04-29 Pharmazeutische dosierungsform von amorphem nilfenavir mesylat ATE282428T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28841001P 2001-05-03 2001-05-03
PCT/EP2002/004711 WO2002089835A2 (en) 2001-05-03 2002-04-29 Pharmaceutical dosage form of amorphous nelfinavir mesylate

Publications (1)

Publication Number Publication Date
ATE282428T1 true ATE282428T1 (de) 2004-12-15

Family

ID=23106974

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02748680T ATE282428T1 (de) 2001-05-03 2002-04-29 Pharmazeutische dosierungsform von amorphem nilfenavir mesylat

Country Status (36)

Country Link
US (1) US7014866B2 (de)
EP (1) EP1390063B1 (de)
JP (1) JP4101661B2 (de)
KR (1) KR100554816B1 (de)
CN (1) CN1255185C (de)
AR (1) AR034320A1 (de)
AT (1) ATE282428T1 (de)
BG (1) BG108311A (de)
BR (1) BR0209325A (de)
CA (1) CA2444116C (de)
CZ (1) CZ20033211A3 (de)
DE (1) DE60201988T2 (de)
EA (1) EA006627B1 (de)
EC (1) ECSP034827A (de)
ES (1) ES2231717T3 (de)
GE (1) GEP20053466B (de)
GT (1) GT200200079A (de)
HR (1) HRP20030873B1 (de)
HU (1) HU229938B1 (de)
IL (2) IL158306A0 (de)
IS (1) IS7010A (de)
JO (1) JO2401B1 (de)
MA (1) MA27018A1 (de)
MX (1) MXPA03009971A (de)
MY (1) MY128509A (de)
NO (1) NO20034689L (de)
NZ (1) NZ528689A (de)
PA (1) PA8544501A1 (de)
PE (1) PE20021159A1 (de)
PL (1) PL366998A1 (de)
PT (1) PT1390063E (de)
RS (1) RS83503A (de)
SK (1) SK14572003A3 (de)
TW (1) TWI234461B (de)
UA (1) UA76463C2 (de)
WO (1) WO2002089835A2 (de)

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001034119A2 (en) 1999-11-12 2001-05-17 Abbott Laboratories Inhibitors of crystallization in a solid dispersion
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
CA2398226A1 (en) * 2002-01-28 2003-07-28 Pfizer Inc. Increased-dosage nelfinavir tablet and method of making same
WO2005004868A1 (ja) * 2003-07-15 2005-01-20 Arigen, Inc. 抗コロナウイルス剤
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8974823B2 (en) * 2003-12-31 2015-03-10 Bend Research, Inc. Solid compositions of low-solubility drugs and poloxamers
JP5228488B2 (ja) * 2004-12-03 2013-07-03 メルク・シャープ・アンド・ドーム・コーポレーション 放出速度調節組成物を含有しているカルボキサミドｈｉｖインテグラーゼ阻害薬の医薬配合物
SI1928427T1 (sl) * 2005-09-23 2010-03-31 Hoffmann La Roche Nove formulacije za doziranje
ES2350497T3 (es) * 2005-12-14 2011-01-24 F. Hoffmann-La Roche Ag Formulación de profármacos para el vhc.
ATE482690T1 (de) * 2005-12-14 2010-10-15 Hoffmann La Roche Hcv-prodrug-formulierung
WO2008017867A2 (en) * 2006-08-10 2008-02-14 Cipla Limited Antiretroviral solid oral composition with at least one water insoluble polymer
KR101462693B1 (ko) 2006-08-16 2014-11-17 노파르티스 아게 고도 결정질 치료용 화합물의 고체 분산체 제조 방법
CA2669938C (en) * 2006-11-15 2016-01-05 Abbott Laboratories Solid pharmaceutical dosage formulations
CA2681628C (en) 2007-03-16 2016-10-18 Concert Pharmaceuticals, Inc. Inhibitors of cholesterol ester transfer protein
KR20100105802A (ko) * 2007-04-19 2010-09-29 콘서트 파마슈티컬즈, 인크. 중수소화된 모르폴리닐 화합물
ES2401914T3 (es) 2007-04-25 2013-04-25 Concert Pharmaceuticals Inc. Análogos de Cilostazol
CA2630084A1 (en) * 2007-04-30 2008-10-30 Mark Andreychuk Coiled tubing with retainer for conduit
US9194512B2 (en) 2007-04-30 2015-11-24 Mark Andreychuk Coiled tubing with heat resistant conduit
MX385316B (es) 2007-05-01 2025-03-18 Concert Pharmaceuticals Inc Compuestos de morfinano.
AU2008247818B2 (en) 2007-05-01 2011-10-20 Sun Pharmaceutical Industries, Inc. Morphinan compounds
WO2008137461A1 (en) * 2007-05-01 2008-11-13 Concert Pharmaceuticals Inc. Naphthyl(ethyl) acetamides
EP4183787A1 (de) 2007-05-01 2023-05-24 Concert Pharmaceuticals Inc. Morphinanverbindungen
KR20120029480A (ko) 2007-06-12 2012-03-26 콘서트 파마슈티컬즈, 인크. 아자펩티드 유도체
EP2212298B1 (de) * 2007-10-18 2013-03-27 Concert Pharmaceuticals Inc. Deuteriertes etravirin
WO2009052391A1 (en) * 2007-10-19 2009-04-23 Purdue Research Foundation Solid formulations of crystalline compounds
ITMI20080227A1 (it) * 2008-02-13 2009-08-14 Felice Vinati '' dispositivo di sicurezza per apparati di sollevamento a fune ''
KR20100121527A (ko) 2008-02-29 2010-11-17 콘서트 파마슈티컬즈, 인크. 치환된 잔틴 유도체
US20110160253A1 (en) * 2008-05-28 2011-06-30 Harbeson Scott L Deuterated tizanidine
US20100221221A1 (en) * 2008-08-12 2010-09-02 Concert Pharmaceuticals Inc. N-phenyl-2-pyrimidineamine derivatives
MX361542B (es) 2008-09-19 2018-12-10 Concert Pharmaceuticals Inc Compuestos de morfinan.
US20120083487A1 (en) 2008-10-30 2012-04-05 Amanda Thomas Combination of morphinan compounds and antidepressant for the treatment of pseudobulbar affect, neurolgical diseases, intractable and chronic pain and brain injury
US20120053169A1 (en) 2008-10-30 2012-03-01 Amanda Thomas Combination of morphinan compounds and antidepressant for the treatment of pseudobulbar affect, neurological diseases, intractable and chronic pain and brain injury
US9096646B2 (en) 2008-11-04 2015-08-04 Anchor Therapeutics, Inc. CXCR4 receptor compounds
WO2010065755A1 (en) 2008-12-04 2010-06-10 Concert Pharmaceuticals, Inc. Deuterated pyridinones
US20110053961A1 (en) 2009-02-27 2011-03-03 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
BRPI1009199A2 (pt) 2009-03-17 2016-03-08 Concert Pharmaceuticals Inc compostos de pirazinoisoquinolina
US20120244122A1 (en) 2009-05-28 2012-09-27 Masse Craig E Peptides for the Treatment of HCV Infections
US8501738B2 (en) 2009-06-23 2013-08-06 Concert Pharmaceuticals, Inc. Substituted triazolo-pyridazine derivatives
US20110015154A1 (en) * 2009-07-20 2011-01-20 Kellermann Gottfried H Supporting acetylcholine function
WO2011047315A1 (en) 2009-10-15 2011-04-21 Concert Pharmaceuticals, Inc. Subsitituted benzimidazoles
US20110098265A1 (en) * 2009-10-28 2011-04-28 Neuroscience, Inc. Methods for reducing cravings and impulses associated with addictive and compulsive behaviors
WO2011060216A1 (en) 2009-11-12 2011-05-19 Concert Pharmaceuticals Inc. Substituted azaindoles
US20140018379A1 (en) 2010-02-18 2014-01-16 Concert Pharmaceuticals Inc. Pyrimidine derivatives
WO2011106703A2 (en) 2010-02-26 2011-09-01 Anchor Therapeutics, Inc. Cxcr4 receptor compounds
US8575361B2 (en) 2010-03-02 2013-11-05 Concert Pharmaceuticals Inc. Tetrahydronaphthalene derivatives
US8513434B2 (en) 2010-03-02 2013-08-20 Concert Pharmaceuticals Inc. Tetrahydronaphthalene derivatives
WO2011157721A2 (en) 2010-06-14 2011-12-22 Ratiopharm Gmbh Ivabradine-containing pharmaceutical composition
EP2616467A1 (de) 2010-09-13 2013-07-24 Concert Pharmaceuticals Inc. Substituierte azaindole
EP2455068A1 (de) * 2010-11-09 2012-05-23 F. Hoffmann-La Roche AG Pharmazeutische Zusammensetzung zur Behandlung von HCV-Infektionen
WO2012065028A2 (en) 2010-11-11 2012-05-18 Concert Pharmaceuticals Inc. Substituted tetracyclines
WO2012079075A1 (en) 2010-12-10 2012-06-14 Concert Pharmaceuticals, Inc. Deuterated phthalimide derivatives
US8447329B2 (en) 2011-02-08 2013-05-21 Longsand Limited Method for spatially-accurate location of a device using audio-visual information
EP2678337A1 (de) 2011-02-25 2014-01-01 Concert Pharmaceuticals Inc. 2-amino-naphthyridin-derivate
WO2012129381A1 (en) 2011-03-22 2012-09-27 Concert Pharmaceuticals Inc. Deuterated preladenant
WO2012151361A1 (en) 2011-05-03 2012-11-08 Concert Pharmaceuticals Inc. Carbamoylpyridone derivatives
WO2012154728A1 (en) 2011-05-10 2012-11-15 Concert Pharmaceuticals Inc. Deuterated n-butyl bumetanide
DK3235812T3 (da) 2011-05-18 2019-11-25 Vertex Pharmaceuticals Europe Ltd Deutererede derivater af ivacaftor
WO2013013052A1 (en) 2011-07-19 2013-01-24 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
FR2985177B1 (fr) * 2012-01-02 2016-04-01 Oreal Composition cosmetique solide aqueuse comprenant de l'alkylcellulose, au moins deux huiles non volatiles et au moins deux agents tensioactifs
EP2802596A1 (de) 2012-01-09 2014-11-19 Anchor Therapeutics, Inc. Apj-rezeptorverbindungen
WO2013130849A1 (en) 2012-02-29 2013-09-06 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
KR20150002779A (ko) 2012-04-13 2015-01-07 콘서트 파마슈티컬즈, 인크. 치환된 크산틴 유도체
US9249093B2 (en) 2012-04-20 2016-02-02 Concert Pharmaceuticals, Inc. Deuterated rigosertib
DK3882249T3 (da) 2012-06-15 2025-08-25 Sun Pharmaceutical Ind Inc Deutererede derivater af ruxolitinib
EP2885267B1 (de) 2012-07-12 2018-09-05 Concert Pharmaceuticals, Inc. Deuteriertes idebenon
EP3492472A1 (de) 2012-08-17 2019-06-05 Concert Pharmaceuticals Inc. Deuteriertes baricitinib mit verbesserter metabolischer stabilität als jak1 und jak2 kinase inhibitor zur behandlung von rheumatoider arthritis
WO2014078842A1 (en) 2012-11-19 2014-05-22 Concert Pharmaceuticals, Inc. Deuterated cftr potentiators
US20150299166A1 (en) 2012-12-20 2015-10-22 Concert Pharmaceuticals, Inc. Deuterated alk inhibitors
ES2882258T3 (es) 2012-12-21 2021-12-01 Mayo Found Medical Education & Res Métodos y materiales para tratar estenosis de la válvula aórtica calcificada
WO2014110322A2 (en) 2013-01-11 2014-07-17 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
CA2904054A1 (en) 2013-03-15 2014-09-25 Concert Pharmaceuticals, Inc. Deuterated palbociclib
CA2906396A1 (en) 2013-03-15 2014-09-25 Concert Pharmaceuticals Inc. Inhibitors of the enzyme udp-glucose: n-acyl-sphingosine glucosyltransferase
HU231191B1 (hu) 2013-04-15 2021-08-30 Szegedi Tudományegyetem Izotóp tartalmú morfin molekulák
WO2015010045A1 (en) 2013-07-18 2015-01-22 Anchor Therapeutics, Inc. Apj receptor compounds
WO2015009889A1 (en) 2013-07-18 2015-01-22 Concert Pharmaceuticals, Inc. Deuterated intedanib derivatives and their use for the treatment of proliferative disorders
US9676790B2 (en) 2013-08-30 2017-06-13 Concert Pharmaceuticals, Inc. Substituted thienotriazolodiazapines
EP3105232B1 (de) 2014-02-10 2019-08-28 Concert Pharmaceuticals Inc. Substituierte triazolobenzodiazepine
US20170216296A1 (en) 2014-04-18 2017-08-03 Concert Pharmaceuticals, Inc. Methods of treating hyperglycemia
WO2015179772A1 (en) 2014-05-23 2015-11-26 Concert Pharmaceuticals, Inc. Deuterated phenylquinazolinone and phenylisoquinolinone compounds
PE20170664A1 (es) 2014-06-06 2017-06-10 Res Triangle Inst Agonistas del receptor de apelina(apj) y usos de los mismos
EP4180041A1 (de) 2014-08-07 2023-05-17 Mayo Foundation for Medical Education and Research Verbindungen und verfahren zur behandlung von krebs
WO2016061488A1 (en) 2014-10-17 2016-04-21 Concert Pharmaceuticals, Inc. Amine reuptake inhibitors
WO2016073545A1 (en) 2014-11-06 2016-05-12 Concert Pharmaceuticals, Inc. Phenyloxadiazole benzoic acids
WO2016089814A1 (en) 2014-12-02 2016-06-09 Concert Pharmaceuticals, Inc. Deuterated analogues of daclatasvir
WO2016094011A1 (en) * 2014-12-11 2016-06-16 Merck Sharp & Dohme Corp. Crystal forms of a ccr5 antagonist
CN105769809A (zh) * 2014-12-23 2016-07-20 上海星泰医药科技有限公司 提高生物利用度的雷尼司他及其制备方法
WO2016105547A1 (en) 2014-12-24 2016-06-30 Concert Pharmaceuticals, Inc. Deuterated dasabuvir
WO2016109795A1 (en) 2014-12-31 2016-07-07 Concert Pharmaceuticals, Inc. Deuterated funapide and difluorofunapide
EP3265440A1 (de) 2015-03-06 2018-01-10 Concert Pharmaceuticals Inc. Deuteriertes emricasan
HK1249893A1 (zh) 2015-03-31 2018-11-16 Vertex Pharmaceuticals (Europe) Limited 氘代vx-661
US10683305B2 (en) 2015-04-27 2020-06-16 Concert Pharmaceuticals, Inc. Deuterated OTX-015
WO2017020002A1 (en) 2015-07-30 2017-02-02 Concert Pharmaceuticals, Inc. Deuterated morphinan compounds for use in treating agitation
WO2017020005A1 (en) 2015-07-30 2017-02-02 Concert Pharmaceuticals, Inc. Morphinan compounds for use in treating agitation
US20180353500A1 (en) 2015-09-21 2018-12-13 Vertex Pharmaceuticals (Europe) Limited Administration of deuterated cftr potentiators
US11267777B2 (en) 2015-11-19 2022-03-08 Concert Pharmaceuticals, Inc. Deuterated EPI-743
PE20190258A1 (es) 2015-12-09 2019-02-25 Res Triangle Inst Antagonistas del receptor de la apelina (apj) mejorados y usos de los mismos
WO2017147003A1 (en) 2016-02-26 2017-08-31 Novobiotic Pharmaceuticals, Llc Novel macrocyclic antibiotics and uses thereof
LT3452039T (lt) 2016-05-04 2024-10-25 Sun Pharmaceutical Industries, Inc. Plaukų slinkimo sutrikimo gydymas deuterintais jak inhibitoriais
CN115215801A (zh) 2016-07-04 2022-10-21 雅芳制药公司 氘代右美沙芬的合成方法
CN109789103A (zh) 2016-08-01 2019-05-21 布里格姆妇女医院 用于递送蛋白质和肽的颗粒
US10696677B2 (en) 2016-12-21 2020-06-30 Research Triangle Institute Diaryl purine derivatives with improved bioavailability
EP3589659B1 (de) 2017-02-28 2025-04-09 Mayo Foundation for Medical Education and Research Kombinationen zur verwendung bei der behandlung von krebs
US11278025B2 (en) 2017-05-17 2022-03-22 The General Hospital Corporation Antibiotic compounds
CA3063953A1 (en) 2017-05-19 2018-11-22 Superb Wisdom Limited Derivatives of resiquimod
AU2018371784B2 (en) 2017-11-22 2024-10-17 Sun Pharmaceutical Industries, Inc. Deuterated analogs of D-serine and uses thereof
US11243207B2 (en) 2018-03-29 2022-02-08 Mayo Foundation For Medical Education And Research Assessing and treating cancer
MX2021012409A (es) 2019-04-10 2021-11-12 Mayo Found Medical Education & Res Metodos y materiales para el tratamiento dependiente del genero de la disfuncion cardiovascular.
WO2021236139A1 (en) 2020-05-21 2021-11-25 Concert Pharmaceuticals, Inc. Novel deuterated jak inhibitor and uses thereof
CA3184471A1 (en) 2020-05-27 2021-12-02 The Penn State Research Foundation Antibacterial compounds
IL302401A (en) 2020-10-28 2023-06-01 Sun Pharmaceutical Ind Inc Regimens for the treatment of hair loss disorders with faded JAC inhibitors
JP2024507574A (ja) 2021-02-25 2024-02-20 リサーチ トライアングル インスティテュート アペリン受容体アゴニストとしてのヘテロアリール誘導体
CN118159272A (zh) 2021-08-11 2024-06-07 太阳医药工业公司 用氘化的jak抑制剂来治疗脱发病症
EP4384173A1 (de) 2021-08-12 2024-06-19 Sun Pharmaceutical Industries, Inc. Behandlung von auf jak-hemmung ansprechenden erkrankungen mit prodrugs von jak-hemmern
EP4518863A1 (de) 2022-05-04 2025-03-12 Sun Pharmaceutical Industries, Inc. Dosierungsschemata zur behandlung mit deuterierten jak-hemmern

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5281420A (en) 1992-05-19 1994-01-25 The Procter & Gamble Company Solid dispersion compositions of tebufelone
IE80467B1 (en) * 1995-07-03 1998-07-29 Elan Corp Plc Controlled release formulations for poorly soluble drugs
US5834472A (en) 1996-05-24 1998-11-10 Schering Corporation Antifungal composition with enhanced bioavailability
US6232333B1 (en) * 1996-11-21 2001-05-15 Abbott Laboratories Pharmaceutical composition
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
US6001851A (en) 1997-03-13 1999-12-14 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
ES2248908T7 (es) * 1997-06-06 2014-11-24 Depomed, Inc. Formas de dosificación de fármacos por vía oral y retención gástrica para liberación continuada de fármacos altamente solubles
AU8145198A (en) * 1997-06-16 1999-01-04 Vertex Pharmaceuticals Incorporated Methods of increasing the bioavailability of stable crystal polymorphs of a compound
ES2236943T3 (es) * 1997-09-19 2005-07-16 Shire Laboratories Inc. Perlas de disolucion solida.
DE60017444T2 (de) * 1999-11-12 2006-02-09 Abbott Laboratories, Abbott Park Pharmazeutische formulierungen auf basis fester dispersionen
US6499984B1 (en) * 2000-05-22 2002-12-31 Warner-Lambert Company Continuous production of pharmaceutical granulation

Also Published As

Publication number Publication date
TWI234461B (en) 2005-06-21
PT1390063E (pt) 2005-03-31
CA2444116A1 (en) 2002-11-14
MXPA03009971A (es) 2004-02-12
HRP20030873A2 (en) 2005-08-31
PL366998A1 (en) 2005-02-07
CA2444116C (en) 2009-01-20
PA8544501A1 (es) 2002-11-18
PE20021159A1 (es) 2002-12-20
NO20034689D0 (no) 2003-10-20
EA200301166A1 (ru) 2004-04-29
AR034320A1 (es) 2004-02-18
DE60201988D1 (de) 2004-12-23
US7014866B2 (en) 2006-03-21
HUP0401238A2 (hu) 2004-12-28
MY128509A (en) 2007-02-28
GEP20053466B (en) 2005-02-25
KR20040007523A (ko) 2004-01-24
ES2231717T3 (es) 2005-05-16
NZ528689A (en) 2005-03-24
EP1390063A2 (de) 2004-02-25
EA006627B1 (ru) 2006-02-24
HU229938B1 (en) 2015-01-28
ECSP034827A (es) 2003-12-24
EP1390063B1 (de) 2004-11-17
MA27018A1 (fr) 2004-12-20
BR0209325A (pt) 2004-07-20
DE60201988T2 (de) 2005-12-15
RS83503A (sr) 2006-10-27
CN1255185C (zh) 2006-05-10
UA76463C2 (en) 2006-08-15
CN1547484A (zh) 2004-11-17
SK14572003A3 (sk) 2004-12-01
US20030021840A1 (en) 2003-01-30
KR100554816B1 (ko) 2006-02-22
HK1070285A1 (en) 2005-06-17
JP2004527569A (ja) 2004-09-09
HUP0401238A3 (en) 2012-09-28
IL158306A (en) 2008-11-03
HRP20030873B1 (en) 2006-04-30
JO2401B1 (en) 2007-06-17
IS7010A (is) 2003-10-30
GT200200079A (es) 2002-12-05
BG108311A (bg) 2004-12-30
IL158306A0 (en) 2004-05-12
NO20034689L (no) 2003-10-20
CZ20033211A3 (cs) 2004-09-15
JP4101661B2 (ja) 2008-06-18
WO2002089835A2 (en) 2002-11-14
WO2002089835A3 (en) 2003-05-01

Similar Documents

Publication Publication Date Title
DE60201988D1 (de) Pharmazeutische dosierungsform von amorphem nilfenavir mesylat
NO20030627D0 (no) Hydrogel-drevet medikament doseringsform
ATE307571T1 (de) Pharmazeutische formulierung enthaltend bicalutamid
DE60201859D1 (de) Pharmazeutische Verwendung von N-Carbamoylazol-Derivate
NO20033384D0 (no) Farmasöytisk formulering
NO20022970D0 (no) Hydrogel-drevet medikamentdoseringsform
ATE334656T1 (de) Flüssige pharmazeutische zusammensetzung
DE50212273D1 (de) Pharmazeutische salze von 1-phenyl-3-dimethylamino-propan-verbindungen
ATE317260T1 (de) Pharmazeutische formulierungen mit platinderivaten
ATE468324T1 (de) Pharmazeutische zusammensetzung
EE05475B1 (et) Superantigeeni sisaldav konjugaat, konjugaadi kasutamine ja konjugaati sisaldav farmatseutiline kompositsioon
ATE320256T1 (de) Succinate des 5,8,14-triazatetracyclo(10.3.1.0 2, 11 .0 4,9 )-hexadeca-2(11),3,5,7,9,-pentaens und pharmazeutische zusammensetzungen
NO20035627D0 (no) Farmasöytisk formulering
DE60217390D1 (de) Bicalutamid enthaltende pharmazeutische zusammensetzung
DE60129238D1 (de) Pharmazeutische zusammensetzung
DE10291905D2 (de) Pharmazeutische Zusammensetzung
ATE439354T1 (de) Pharmazeutische salze von reboxetin
NO20033162L (no) Farmasöytisk tablett omfattende paroksetinmesylat
ATE350029T1 (de) Pharmazeutische zusammensetzung enthaltend gamma- butyrobetain
DE60214533D1 (de) Pyridoindolonderivate und antikrebsmittel enthaltende pharmazeutische mischungen
DE10107261B4 (de) Pharmazeutische Zusammensetzung
ATE349213T1 (de) Nasale pharmazeutische zusammensetzung von piribedil
EE200300563A (et) Bensüülaminopürimidiiniühendid, nende kasutamine ja ravim
NO20041236L (no) Farmasoytisk formulering
FI20011192A0 (fi) Flavonoidilääkeaine ja annostusmuoto, sen valmistus ja käyttö

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1390063

Country of ref document: EP